<DOC>
	<DOCNO>NCT00004323</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate efficacy relate , HLA-identical bone marrow transplantation follow cyclophosphamide ( CTX ) antithymocyte globulin patient aplastic anemia . II . Evaluate efficacy relate , HLA-nonidentical bone marrow transplantation follow CTX total-body irradiation/total-lymphoid irradiation patient aplastic anemia .</brief_summary>
	<brief_title>Phase II Study Bone Marrow Transplantation Using Related Donors Patients With Aplastic Anemia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients HLA-identical donor receive cyclophosphamide/mesna , antithymocyte globulin ( ATG ) , methylprednisolone ( MePRDL ) , follow allogeneic marrow transplantation . Patients HLA-nonidentical ( 5/6 4/6 ) donor systemic reaction ATG receive dosage myeloablative chemotherapy rescue . In addition , patient treat total-body irradiation , total-lymphoid irradiation , methotrexate . All patient receive MePRDL cyclosporine graft-versus-host prophylaxis .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Severe aplastic anemia 2 follow criterion : Polymorphonuclear neutrophils 0.5 x 10 ninth/L Platelets 20 x 10 ninth/L Reticulocytes 30 x 10 ninth/L Hypocellular bone marrow Related donor age 6 week , match least 4 6 HLA A , B , DRI locus , follow : HLAidentical family member patient age less 40 year HLAnonidentical family member patient age less 55 year fail antithymocyte globulin immunosuppressive therapy The follow eligible transplantation initial therapy : Patients age less 40 year HLAmatched donor Patients age 4045 year HLAidentical donor No neoplastic preneoplastic evolution Patient Characteristics Age : Under 40 ( 55 ATG failure ) Hepatic : No severe liver dysfunction Renal : No severe renal dysfunction Cardiovascular : No severe cardiac dysfunction Other : No organ dysfunction would compromise survival transplant No HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>aplastic anemia</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>